199 related articles for article (PubMed ID: 10483579)
21. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
22. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
23. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
26. [Results of a multicenter study of Rebif-22 mcg administration in Russia].
Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639
[TBL] [Abstract][Full Text] [Related]
27. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
28. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
29. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
[TBL] [Abstract][Full Text] [Related]
30. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
31. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
[TBL] [Abstract][Full Text] [Related]
32. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
[TBL] [Abstract][Full Text] [Related]
33. [Interferon beta-1b (Betaferon)therapy in patients with relapsing-remitting multiple sclerosis: findings of a prospective, multi-center study of disease progression].
Oentrich W; Dose T; Friedmann D; Haupts M; Haller P; Hartung HP; Walther EU; König N; Schröder G; Stürzebecher CS
Nervenarzt; 2001 Apr; 72(4):286-92. PubMed ID: 11320864
[TBL] [Abstract][Full Text] [Related]
34. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
[TBL] [Abstract][Full Text] [Related]
35. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
36. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N; Sørensen PS
Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
38. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
[TBL] [Abstract][Full Text] [Related]
39. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
40. [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].
Fertl E; Krichmayr M
Wien Med Wochenschr; 2008; 158(3-4):98-109. PubMed ID: 18330526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
